中
  • HOME

  • Company

    • GenFleet Overview
    • Vision & Mission
    • Management Team
    • Awards & Honors
    • Company History
    • CSR Philosophy
  • Science

    • Our Pipeline
    • Publications
    • R&D System
  • Media

    • Press Release
    • Media Coverage
  • Investors

    • Institutional Investors
  • Careers

    • Overview
    • Culture
    • Highlights
    • Benefits
  • Contact

jinfangLOGOzuhejihekouhao-05.png

HOME

Company

  • GenFleet Overview
  • Vision & Mission
  • Management Team
  • Awards & Honors
  • Company History
  • CSR Philosophy

Science

  • Our Pipeline
  • Publications
  • R&D System

Media

  • Press Release
  • Media Coverage

Investors

  • Institutional Investors

Careers

  • Overview
  • Culture
  • Highlights
  • Benefits

Contact

中
Home
Media
Press Release
  • GenFleet Announces GFH009 Granted with FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia

    Preliminary results from GFH009 monotherapy study for relapsed/refractory hematological malignancies demonstrated favorable safety/tolerability of GFH009 with no unexpected dose limiting toxicities or hematological toxicities difficult to determine in patients. With regard to efficacy, the study exhibited GFH009’s anti-tumor activity of up to 77.3% bone marrow blast reduction and desired levels of MCL1 & MYC suppression in peripheral blood with decrease in MCL1 or MYC observed in 97% (66/68)

    Oct 12, 2023
  • GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

    The phase I, multi-center trial of GFH009 monotherapy for relapsed/refractory hematological malignancies has completed its dose escalation portion in both China and the US. Preliminary results demonstrated favorable safety/tolerability and promising clinical efficacy of GFH009. Complete or partial responses were observed in acute myeloid leukemia and lymphoma patients; four PTCL patients (36.4%) were observed with clinical response including one in a continuous treatment for over 48 weeks. The r

    Oct 10, 2023
  • GenFleet Therapeutics Enters Discovery and Development Collaboration with Verastem to Advance Three Oncology Programs in Areas of High Unmet Need

    The terms of the agreement include combined upfront, research support and option payments to GenFleet of $11.5 million for the first program, with potential total deal size across all programs up to $625.5 million excluding royalties.

    Aug 28, 2023
  • First Patient Dosed in Phase IIa Combination Study of GFH009 with Venetoclax and Azacitidine Treating Acute Myeloid Leukemia Patients

    The Phase 2a clinical trial is an open label, single arm, multi-center study that is designed to evaluate safety, tolerability, and efficacy at two dose levels of GFH009 (once weekly 45 mg or 60 mg) in combination with aza/ven. The study will enroll up to 20 r/r AML patients, 10 patients per dose level, all of whom will receive standard doses of aza/ven after they became unresponsive to venetoclax combinations including aza/ven, with the addition of GFH009. Treatment will continue for as long as

    Jul 03, 2023
  • Phase I Data of GFH925 Monotherapy Treating CRC Released at ASCO

    Favorable safety/tolerability and promising antitumor activity of GFH925 monotherapy were observed among advanced colorectal cancer (CRC) patients harboring KRASG12C mutation according to preliminary results from a pooled analysis of two phase I studies(NCT05005234, NCT05497336).

    Jun 06, 2023
  • GFH925 Receives Breakthrough Designation as Monotherapy for Previously Treated Advanced Colorectal Carcinoma

    The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI351 (GFH925) for the treatment of previously treated advanced colorectal carcinoma (CRC) patients with KRASG12C mutation.

    May 15, 2023
  • Phase I Data for GFH925 Monotherapy Presented at 2023 AACR

    Favorable safety and tolerability and promising antitumor activity of GFH925 (KRASG12C inhibitor) monotherapy were observed in previously-treated advanced NSCLC harboring KRASG12C mutation.

    Apr 19, 2023
  • GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting

    The data of cerebrospinal fluid (CSF) analysis from subjects receiving 120 mg daily administration suggest that GFH312 has exposure in the CNS and may potentially be useful for treating neurological indications. The phase I study of GFH312 was completed in Australia and GenFleet has been granted with the FDA approval for phase II study of GFH312.

    Mar 10, 2023
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Prev
Next
jinfangLOGOzuhejihekouhao-08.png
Company
Science
Media
Investors
Careers
Contact
GenFleet Therapeutics (Shanghai)

1206 Zhangjiang Road, Building A, Shanghai

021-6882 1388

201203

GenFleet Therapeutics (Zhejiang)

1 Yunhai Road, Building 3 (Southern Division), Level 4, Shaoxing City, Zhejiang Province

0575-8258 6890

312000

Offical Wechat
qrcode_for_gh_ae7817a32e15_258.jpg
GenFleeter Wechat
jinfangren-121.jpg
Copyright © 2021 GenFleet Therapeutics (Shanghai) Inc  |  沪ICP备18006424号-1